A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

February 28, 2027

Conditions

Soft Tissue Sarcoma

Interventions

DRUG

Tigilanol Tiglate

Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.

Trial Locations (1)

RECRUITING

Memorial Sloan Kettering Cancer Centre, New York

All Listed Sponsors

lead

QBiotics Group Limited

INDUSTRY